A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection

Vaccine

Volumn 29, Issue 4, 2011, Pages 831-838

  Lima, Danielle Malta ^a   Paula, Sérgio Oliveira de ^b   França, Rafael Freitas de Oliveira ^a   Palma, Patrícia V B ^a   Morais, Fabiana R ^a   Gomes Ruiz, Alessandra Cristina ^a   Aquino, Maria Teresa Prudente de ^a   Fonseca, Benedito Antonio Lopes da ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

Author keywords

Dengue 4; Plasmid; Recombinant DNA; Vaccine

Indexed keywords

CYTOKINE; DENV 4 DNA VACCINE; DNA VACCINE; M PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 4; DRUG SCREENING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPRECIPITATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINANT PLASMID; SPLEEN; VIRUS GENE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL PROLIFERATION; DENGUE; DENGUE VIRUS; FEMALE; GENETIC VECTORS; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; PLASMIDS; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VIRAL STRUCTURAL PROTEINS;

EID: 78650538214     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.078     Document Type: Article

References (41)

1. Halstead S.B. Pathogenesis of dengue-challenges to molecular-biology. Science 1988, 239(4839):476-481.
2. Jacobs M. Dengue: emergence as a global public health problem and prospects for control. Trans R Soc Trop Med Hyg 2000, 94(1):7-8.
3. Tolle M.A. Mosquito-borne diseases. Curr Probl Pediatr Adolesc Health Care 2009, 39(4):97-140.
4. Chambers T.J., Tsai T.F., Pervikov Y., Monath T.P. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine 1997, 15(14):1494-1502.
5. Mellado-Sánchez G., García-Machorro J., Sandoval-Montes C., Gutiérrez-Castañeda B., Rojo-Domínguez A., García-Cordero J., et al. A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model. Arch Virol 2010, 155(6):847-856.
6. Blaney J.E., Durbin A.P., Murphy B.R., Whitehead S.S. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol 2006, 19(1):10-32.
7. Eckels K.H., Dubois D.R., Putnak R., Vaughn D.W., Innis B.L., Henchal E.A., et al. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 2003, 69(6):12-16.
8. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001, 75(16):7290-7304.
9. Halstead S.B, Marchette N.J. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 2003, 69(6):5-11.
10. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24(9):1238-1241.
11. Mathenge E.G.M., Parquet M.D.C., Funakoshi Y., Houhara S., Wong P.F., Ichinose A., et al. Fusion PCR generated Japanese encephalitis virus/dengue 4 virus chimera exhibits lack of neuroinvasiveness, attenuated neurovirulence, and a dual-flavi immune response in mice. J Gen Virol 2004, 85:2503-2513.
12. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000, 18:44-47.
13. Durbin A.P., McArthur J.H., Marron J.A., Blaney J.E., Thumar B., Wanionek K., et al. rDEN2/4 Delta 30(ME), a live attenuated chimeric dengue serotype 2 vaccine, is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006, 2(6):255-260.
14. Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003, 69(6):48-60.
15. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax (TM)-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity. Hum Vaccin 2006, 2(2):60-67.
16. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80(2):302-311.
17. Tighe H., Corr M., Roman M., Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998, 19(2):89-97.
18. Simmons M., Burgess T., Lynch J., Putnak R. Protection against dengue virus by non replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010, 396(2):280-288.
19. Imoto J., Konishi E. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine 2007, 25(6):1076-1084.
20. Raviprakash K., Apt D., Brinkman A., Skinner C., Yang S.M., Dawes G., et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006, 353(1):166-173.
21. Russell P.K., Nisalak A. Dengue virus identification by plaque reduction neutralization test. J Immunol 1967, 99(2):291-296.
22. Rigau-Perez J.G., Clark G.G., Gubler D.J., Reiter P., Sanders R.J., Vorndam A.V. Dengue and dengue haemorrhagic fever. Lancet 1998, 352(9132):971-977.
23. Innis B.L., Eckels K.H. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 2003, 69(6):1-4.
24. Pang T.K. Vaccines for the prevention of neglected diseases-dengue fever. Curr Opin Biotechnol 2003, 14(3):332-336.
25. Gurunathan S., Wu C.Y., Freidag B.L., Seder R.A. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 2000, 12(4):442-447.
26. Chattergoon M.A., Robinson T.M., Boyer J.D., Weiner D.B. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages antigen-presenting cells. J Immunol 1998, 160(12):5707-5718.
27. De Paula S.O., Lima D., Franca R.F.D., Gomes-Ruiz A.C., da Fonseca BAL. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge. Arch Virol 2008, 153(12):2215-2223.
28. Fonseca B.A.L., Pincus S., Shope R.E., Paoletti E., Mason P.W. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E-induce neutralizing antibodies in mice. Vaccine 1994, 12(3):279-285.
29. Guirakhoo F., Bolin R.A., Roehrig J.T. The murray valley encephalitis-virus prm protein confers acid resistance to virus-particles and alters the expression of epitopes within the r2 domain of e-glycoprotein. Virology 1992, 191(2):921-931.
30. Mota J., Acosta M., Argotte R., Figueroa R., Mendez A., Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 2005, 23(26):3469-3476.
31. Jimenez R.O., da Fonseca BAL. Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice. Vaccine 2000, 19(6):648-654.
32. Heinz F.X., Stiasny K., Puschnerauer G., Holzmann H., Allison S.L., Mandl C.W., et al. Structural-changes and functional control of the tick-borne encephalitis-virus glycoprotein-e by the heterodimeric association with protein prM. Virology 1994, 198(1):109-117.
33. Khanam S., Khanna N., Swaminathan S. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 2006, 24(42/43):6513-6525.
34. Etemad B., Batra G., Raut R., Dahiya S., Khanam S., Swaminathan S., et al. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg 2008, 79(3):353-363.
35. Konishi E., Yamaoka M., Kurane I., Mason P.W. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 2000, 18(11/12):1133-1139.
36. Putnak R., Porter K., Schmaljohn C. DNA vaccines for flaviviruses. Adv Virus Res 2003, 61:445-468.
37. Raviprakash K., Kochel T.J., Ewing D., Simmons M., Phillips I., Hayes C.G., et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000, 18(22):2426-2434.
38. Mangada M.M., Rothman A.L. Altered cytokine responses of dengue-specific CD4(+) T cells to heterologous serotypes. J Immunol 2005, 175(4):2676-2683.
39. Wu S.F., Liao C.L., Lin Y.L., Yeh C.T., Chen L.K., Huang Y.F., et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 2003, 21:3919-3929.
40. Rothman A.L., Kurane I., Ennis F.A. Multiple specificities in the murine CD4(+) and CD8(+) T-cell response to dengue virus. J Virol 1996, 70(10):6540-6546.
41. Tan G.K., Ng J.K., Trasti S.L., Schul W., Yip G., Alonso S. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 2010, 4(4):e672.